Get the Stockscreener App
17.50
1.80%
0.31
After Hours:
17.66
0.16
+0.91%
Seaport Therapeutics Inc stock is traded at $17.50, with a volume of 214.58K.
It is up +1.80% in the last 24 hours and up +0.00% over the past month.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
See More
Previous Close:
$17.19
Open:
$17.19
24h Volume:
214.58K
Relative Volume:
2.25
Market Cap:
$927.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.14%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.53
$17.69
1-Week Range:
$15.00
$17.69
52-Week Range:
$14.85
$19.17
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Name
Seaport Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare SPTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
17.50 | 911.55M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Stock (SPTX) Latest News
Goldman Sachs initiates Seaport Therapeutics stock coverage citing platform validation - Investing.com Canada
Seaport Therapeutics, Inc. Common Stock (SPTX) Competitors - Meyka
Seaport Therapeutics, Inc. Common Stock (SPTX) Fundamental Analysis - Meyka
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Why Is Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Up Today? - Meyka
Why Is Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
Hemab, Seaport surge as clinical-stage biotechs make trading debuts - MSN
SPTX SEC FilingsSEAPORT THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% Stake - TradingView
Seaport Therapeutics (SPTX) Stock Trends and Sentiment 2026 - MarketBeat
Number of shareholders of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Seaport Therapeutics (SPTX) Stock Analysis Report | Financials & Insights - Benzinga
SPTX News Today | Why did Seaport Therapeutics stock drop today? - MarketBeat
Seaport Therapeutics set for Nasdaq debut after raising $255 million in IPO - MSN
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What is the current Price Target and Forecast for Seaport Therapeutics, Inc (SPTX) - Zacks Investment Research
Biotech firm Odyssey raises $279 million in upsized US IPO - 93.3 The Drive
Seaport Therapeutics Stock Price Today | NASDAQ: SPTX Live - Investing.com
The Readout LOUD Podcast Discusses Seaport Therapeutics’ IPO and Obesity Pill Competition on May 7, 2026 - geneonline.com
SPTX: Seaport Therapeutics, IncBrokerage Recommendations Chart - Zacks Investment Research
PureTech-linked entities convert Seaport Therapeutics (SPTX) preferred shares to common - Stock Titan
Seaport Therapeutics, Inc (SPTX) Book Value (Per Share) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
Seaport Therapeutics (SPTX) Stock Price, News & Analysis - MarketBeat
SPTX | Seaport Therapeutics, Inc. Common Institutional Ownership - Quiver Quantitative
SPTX | Seaport Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Diluted earnings per share (diluted EPS) of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
SPTX | Seaport Therapeutics, Inc. Common Stock Data, Price & News - Quiver Quantitative
Seaport Therapeutics, Inc (SPTX) Stock Price Today & Analysis - Gotrade
SPTX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Number of employees of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Some Extraordinary Numbers From Earnings Season - Bloomberg.com
SPTX Technical Analysis & Stock Price Forecast - Intellectia AI
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics (SPTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Diluted earnings per share (diluted EPS) of Seaport Therapeutics, Inc. – BOATS:SPTX - TradingView
Seaport Therapeutics, Inc (SPTX) - Zacks Investment Research
Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move - Yahoo Finance
Seaport Therapeutics, Inc (SPTX) Gross Profit (TTM) - Zacks Investment Research
Seaport Therapeutics, Inc (SPTX) Return On Equity (TTM) - Zacks Investment Research
Seaport and Hemab Therapeutics Launch IPOs, Raising $556 Million - geneonline.com
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to NASDAQ Composite Index - marketscreener.com
Seaport Therapeutics, Inc (SPTX) Price To Cash Flow - Zacks Investment Research
Seaport Therapeutics, Inc (SPTX) Book Value - Zacks Investment Research
Seaport Therapeutics Inc Stock (SPTX) Financials Data
There is no financial data for Seaport Therapeutics Inc (SPTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):